GENPHARMASEC LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.95 INR | -1.02% |
|
-2.50% | -58.24% |
| 05-24 | Genpharmasec Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| 05-24 | Genpharmasec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 273M 3.27M 4.49M | Sales 2023 | 255M 3.06M 4.19M | Capitalization | 861M 10.31M 14.14M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -23.96K -32.85K | Net income 2023 | 11M 132K 181K | EV / Sales 2022 | 5.36 x |
| Net cash position 2022 | 59.41M 712K 976K | Net cash position 2023 | 5.74M 68.71K 94.2K | EV / Sales 2023 | 3.35 x |
| P/E ratio 2022 |
-550
x | P/E ratio 2023 |
77.8
x | Employees | 9 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.02% | ||
| 1 week | -2.50% | ||
| Current month | -3.94% | ||
| 1 month | -17.02% | ||
| 3 months | -18.07% | ||
| 6 months | -58.15% | ||
| Current year | -58.24% |
1 week
1.95
2.00
1 month
1.932.55
Current year
1.938.71
1 year
1.938.71
3 years
1.9312.40
5 years
1.9316.63
10 years
1.2533.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sohan Chaturvedi
DFI | Director of Finance/CFO | 36 | 22-07-03 |
Rajesh Sadhwani
BRD | Director/Board Member | 55 | 19-01-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rajesh Sadhwani
BRD | Director/Board Member | 55 | 19-01-01 |
Sneha Sadhwani
BRD | Director/Board Member | 56 | 19-01-01 |
| Director/Board Member | - | 22-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-20 | 1.95 | -1.02% | 520 861 |
| 24-06-19 | 1.97 | -1.50% | 689,349 |
| 24-06-18 | 2 | 0.00% | 1,221,360 |
| 24-06-14 | 2 | 0.00% | 917,652 |
| 24-06-13 | 2 | 0.00% | 1,199,787 |
Delayed Quote Bombay S.E., June 20, 2024 at 03:45 am
More quotes
Genpharmasec Ltd is an India-based company, which is engaged in the distribution of the lucrative medical and diagnostics device segment. It is engaged in providing technology-based medical and diagnostics devices. The Company operates through two segments: Distribution of Diagnostic Equipmentâs and Investment and trading in Securities. The Company holds rights for distribution of equipments, such as i-STAT Analyzers and its Cartridges manufactured by Abbott Point of Care, USA all over India. The Company also holds distribution rights of Sphingotec Biomarkers and Joinstar System through Rivaara Labs Private Limited.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -58.24% | 13.08M | |
| +52.93% | 803B | |
| +40.67% | 631B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.47% | 243B | |
| +2.13% | 228B | |
| +10.23% | 217B | |
| +6.24% | 164B |
- Stock Market
- Equities
- ADIRASA Stock
